Quadrant Biosciences Clarifi ASD
Dec 04, 2019
Quadrant Biosciences has launched Clarifi ASD, an epigenetic test designed to aid in the diagnosis of autism spectrum disorder in children 18 months through six year of age. Quadrant said the test is based on regulatory RNAs and microbes in the saliva, and is the result of seven years of research in collaboration with SUNY Upstate Medical University and Penn State College of Medicine. Clarifi is a prescription-only, laboratory-developed test that is intended to be used as an additional tool to standard practices and only for children with a clinical suspicion of ASD, the company said. It is available in all states except New York.